Risikoreduktion für vertebrale Frakturen unter Denosumab bei Patienten mit normaler und osteopenischer Knochendichte
暂无分享,去创建一个
P. Hadji | J. Wolff | K. Lippuner | T. Steinle | A. Braun | C. Ke | C. Eisen
[1] S. Perera,et al. Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] A. Katalinic,et al. Krebs in Deutschland 2007/2008 , 2012 .
[3] S. Perera,et al. Vertebral fractures and the misclassification of osteoporosis in men with prostate cancer. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[4] P. Warde,et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. , 2010, The Journal of urology.
[5] F. Saad,et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. , 2009, The Journal of urology.
[6] F. Saad,et al. 7005 Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer , 2009 .
[7] P. Eskildsen,et al. Fracture risk in Danish men with prostate cancer: a nationwide register study , 2007, BJU international.
[8] A. Orsola,et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. , 2007, The Journal of urology.
[9] I. Derweesh,et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. , 2007, The Canadian journal of urology.
[10] P. Kantoff,et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Walsh. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 2000, The Journal of urology.
[12] M. Bolla. Adjuvant Hormonal Treatment with Radiotherapy for Locally Advanced Prostate Cancer , 1998, European Urology.
[13] P. Hadji,et al. Reduktion des Frakturrisikos unter Denosumab bei postmenopausalen Frauen in Abhängigkeit der Behandlungsbedürftigkeit nach DVO-Leitlinie 2009 Reduction of fracture risk with denosumab among women with osteoporosis with or without need for treatment according to DVO 2009 guideline , 2013, Osteologie.
[14] J. Eastham,et al. Original Articles RANDOMIZED CONTROLLED TRIAL OF ZOLEDRONIC ACID TO PREVENT BONE LOSS IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NONMETASTATIC PROSTATE CANCER , 2012 .
[15] F. Saad,et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.
[16] Weiterführende Informationen. DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen , 2009, Osteologie.
[17] B. Clarke,et al. Effect of Once-Weekly Oral Alendronate on Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: A Randomized Trial , 2008 .